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Leptin, a product of the obese gene, is synthesized and released into the circulation in
response to increased energy storage in adipose tissue.  Leptin plays an important role
in the regulation of body weight and energy balance.  However, leptin levels in patients
with malignant tumor have not been fully examined.  The purpose of the present study
is to clarify the clinical implications of leptin levels in the circulation in patients with
gastric cancer.  The subjects were 103 patients with gastric cancer at various stages.
Levels of leptin  in the plasma were determined with a commercially available human
leptin-selective quantitative enzyme immunoassay kit.  There were clear decreasing
trends in leptin levels along with tumor progression in both males and females, and
statistically significant differences were observed in males between stages II and IV,
and in females between stages I and IV.  Plasma leptin levels of females were consistently
higher than those of males when we compared them with patients in the same stages.
Moreover, statistically significant decreases in leptin levels were observed post-
operatively.  However, there were no statistically significant relationships between leptin
levels and clinicopathological findings.  There was a positive correlation between levels
of plasma leptin and values of the body mass index.  These findings may indicate that
plasma leptin levels do not involve factors relevant to specific tumor growth but involve
some tumor-related nutritional status due to tumor progression.  We conclude that
leptin levels are reflected during tumor-bearing status, and these are also useful markers
for both indicating tumor progression and discovering the nutritional status of patients
with gastric cancer.
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Leptin, a product of the obese gene, is synthe-
sized and released into the circulation in re-
sponse to increased energy storage in adipose
tissue (Zhang et al., 1994; Campfield et al., 1995;
Halaas, et al., 1995; Pelleymounter et al., 1995).
Administration of recombinant leptin to obese
mice results in weight loss through both a re-
duction in food intake and an increase in energy
expenditure (Campfield et al., 1995; Halaas et al.,
1995; Pelleymounter et al., 1995).  Therefore, it
has been suggested that leptin plays an impor-
tant role in the regulation of body weight and
energy balance.
In humans, mutations of the leptin gene in
adipose tissue (Montague et al., 1997; Strobel et
al., 1998) and of the leptin receptor gene in the
hypothalamus (Tartaglia et al., 1995; Clement
et al., 1998) induce a decreased leptin level in
the circulation and result in morbid obesity.
Supplementation with recombinant human
leptin for such patients with leptin deficiency
leads to a sustained reduction in body weight as
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chemotherapy because of unresectable post-
operative recurrent tumor from gastric cancer.
The clinicopathological findings were de-
termined according to the rules of the Com-
mittee on the Japanese Classification of Gastric
Carcinoma (Japanese Research Society for
Gastric Cancer, 1993).
Fasting blood samples (early morning be-
fore breakfast) were obtained before surgery or
chemotherapy and stored at –80˚C prior to
analysis.  Postoperative samples were obtained
3 weeks after surgery.
Methods
Levels of leptin in the plasma were determined
with a commercially available human leptin-
selective quantitative enzyme immunoassay
(EIA) kit (Immuno-Biological Laboratories
Co., Ltd., Fujioka, Japan) according to the
manufacturer’s instructions.  In brief, a 100-µL
sample was added to each well of a microtiter
plate, which had been precoated with rabbit
monoclonal antibody specific for human leptin,
and incubated at 37˚C for 1 h.  After washing, a
100-µL solution of horseradish peroxidase-
conjugated antibodies, raised in the rabbit
against human leptin, was added to each well
and incubation was continued at 37˚C for 30
min.  After further washing, color was develop-
ed by incubating each well with 100 µL of the
chromogenic substrate solution.  The colored
reaction product was quantified with a spec-
trometer at 450 nm.  Quantification was achiev-
ed by the construction of a standard curve using
a known concentration of purified, recombinant
human leptin.  The limit of detection using this
kit was 0.78 ng/mL.
The BMI of each patient was calculated by
the following formula :
[ BMI = body weight (kg)/height (m2) ].
Statistical analysis
Data were expressed as mean ± SD.  The mean
values were compared with  Student’s t-test and
two-way analysis of variance.  P values of <
0.05 were considered statistically significant.
a result of a loss of fat (Farooqi et al., 1999), as
is the case with obese mice.  Leptin levels in the
circulation, in general, correlate positively with
indexes of obesity (Maffei et al., 1995; Considine
et al., 1996; Havel et al., 1996; Giannini et al.,
1999), such as body fat or the body mass index
(BMI) (Kahn et al., 1997).
Although there is a gender difference in
leptin levels between males and females, fe-
males have higher plasma leptin concentrations
than males, which is attributable to the relative-
ly greater body fat mass in females (Maffei et
al., 1995; Havel et al., 1996; Giannini et al., 1999).
Whatever the initial concentration, weight loss
due to food restriction is associated with a
decrease in plasma leptin in both obese and
normal weight humans (Maffei et al., 1995;
Rosenbaum et al., 1997).  Therefore, leptin con-
centrations have been regarded as a simple
marker of the extent of obesity in humans.
However, the clinical implications of these
leptin levels in patients with malignant tumor
have not been clearly studied, excluding those
of patients with leptin-producing pregnancy-
related gynecological placental tumor (non-
adipose tissue production of leptin) (Masuzaki
et al., 1997).
Is malignancy-modified nutritional status
reflected in leptin levels or not?  The purpose of
the present study is to examine plasma leptin
levels in relation to BMI values and to clarify
the clinical implications of leptin in patients
with gastric cancer.
Patients and Methods
Patients
The subjects were 103 patients with gastric
cancer at various stages who had been treated in
the First Department of Surgery, Tottori Uni-
versity Hospital, between November 1995 and
April 1998.  Among them, 97 patients (mean
age, 63.3 ± 11.3 years; range, 33 to 85 years; 65
males, 32 females) underwent resection of a
primary gastric tumor, and the remaining 6
patients (mean age, 67.3 ± 8.3 years; range, 56
to 78 years; 1 male, 5 females) underwent
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A Macintosh personal computer system and
StatView software (Abacus Concepts, Inc.,
Berkeley, CA) were used for all statistical
analyses.
Results
Preoperative levels of plasma leptin and BMI in
patients with gastric cancer are shown in Table
1.  Both the mean level of leptin and BMI, in
general, were associated with the tumor pro-
gression of the cancer and decreased along with
stage progression.  Statistically significant de-
Table 2. Levels of preoperative plasma leptin and body mass index (BMI) analyzed in terms of
age and gender
Stage/gender  Age (year) Leptin (ng/mL)        BMI
(mean ± SD)   (mean ± SD) (mean ± SD)
Stage I
   Male [38] 62.0 ± 10.0 2.6 ± 2.2 22.4 ± 2.5
   Female [22] 67.9 ± 12.9 7.2 ± 7.1 22.4 ± 2.6
Stage II
   Male [  7] 58.9 ± 10.3 3.8 ± 4.5 23.8 ± 2.6
   Female [  3] 69.0 ±   6.9 5.8 ± 6.4 23.5 ± 1.8
Stage III
   Male  [  7] 63.9 ± 10.0 2.4 ± 2.2 20.9 ± 3.4
   Female [  5] 59.0 ± 18.5 5.7 ± 5.5 21.5 ± 1.6
Stage IV
   Male [13] 62.4 ±   9.8 1.2 ± 0.8 21.5 ± 3.1
   Female [  2] 57.5 ± 16.2 1.5 ± 0.7 19.3 ± 3.6
Recurrence
   Male [  1] 63.0 0.78 19.5
   Female [  5] 68.2 ±   9.0 1.3 ± 0.7 19.5 ± 1.8
[  ], number of patients.
P < 0.03
P < 0.03
P < 0.001
P < 0.02
P < 0.05
Table 1.  Levels of preoperative plasma leptin and body mass index (BMI)
        Stage Leptin (ng/mL) BMI
(mean ± SD) (mean ± SD)
Stage I [60] 4.3 ± 5.1 22.4 ± 2.5
Stage II [10] 4.3 ± 4.9 23.7 ± 2.3
Stage III [12] 3.8 ± 3.9 21.1 ± 2.7
Stage IV [15] 1.3 ± 0.9 21.2 ± 3.2
Recurrence [  6] 1.2 ± 0.7 19.5 ± 1.6
[  ], number of patients.
P < 0.008
P < 0.008
P < 0.02
P < 0.05P < 0.03
P < 0.03
P < 0.03
creases in leptin levels were found in patients in
stage IV, as compared to patients in stages I, II
and III, respectively.  The differences of mean
value among cancer stages were greater in lep-
tin than in BMI, although values of  SD were
lower in BMI than those in leptin.
Since levels of plasma leptin have been re-
ported to indicate gender and age differences
(Maffei et al., 1995; Havel et al., 1996; Giannini
et al., 1999), these levels were analyzed in
terms of gender and age in each stage (Table 2).
There was no age difference in patients between
males and females in each stage.  However, leptin
levels of females were consistently higher than
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those of males when we compared them in the
same stage, and there was a statistically signif-
icant difference in patients in stage I.  There
were still clear decreasing trends in leptin levels
along with stage progression in both males and
females, and statistically significant differences
were observed in males between stages II and
IV, and in females between stages I and IV.  With
respect to BMI values, there were no gender
differences in each stage.  The decreasing trend
in the value of BMI along with stage progres-
sion was observed in both males and females;
however, it was not so consistent compared
with that in cases of leptin.  In females, there
were statistically significant differences in BMI
between recurrent cases and stage I or II, re-
spectively.
Relationships between the preoperative
levels of plasma leptin and clinicopathological
findings of gastric cancer are shown in Table 3.
In both males and females, although the same
gender showed no statistically significant dif-
ferences between variables (vertical analysis),
plasma leptin had a decreased trend accom-
panied with tumor progression in each variable.
However, gender differences in levels of leptin
were obvious in each variable (horizontal anal-
ysis), as shown in Table 3.
Table 3. Relationship between preoperative plasma leptin levels and clinicopathological
findings
     Variable Leptin (ng/mL) P-value
Male P-value Female P-value (horizontal)‡
[65] (vertical)† [32] (vertical)†
Gross finding
Early cancer 2.6 ± 2.3 [33] NS 7.6 ± 7.1 [17] NS < 0.001
Invasive cancer
Localized 2.2 ± 2.2 [10] 7.8 ± 7.9  [  5]    NS
Infiltrative 1.7 ± 2.0 [22] 4.0 ± 3.9 [10] < 0.04
Histology
Intestinal type 2.7 ± 2.8 [33] NS 6.9 ± 7.6 [14] NS < 0.02
Diffuse type 2.0 ± 1.9 [32] 6.2 ± 5.7 [18] < 0.001
Depth of cancer invasion
T1 2.6 ± 2.3 [34] NS 7.4 ± 7.1 [18] NS < 0.001
T2 2.7 ± 3.3   [  9] 5.7 ± 7.4 [  5]    NS
T3,4 1.9 ± 2.2 [22] 5.3 ± 5.3 [  9] < 0.02
Nodal involvement
Negative 2.6 ± 2.4 [41] NS 7.3 ± 7.0 [24] NS < 0.001
Positive 2.1 ± 2.4 [24] 4.3 ± 4.6 [  8]    NS
Lymphatic vessel invasion
Negative 2.7 ± 2.7 [42] NS 7.5 ± 7.1 [18] NS < 0.001
Positive 1.8 ± 1.7 [23] 5.2 ± 5.7 [14] < 0.02
Blood vessel invasion
Negative 2.5 ± 2.5 [45] NS 7.2 ± 6.8 [26] NS < 0.001
Positive 2.2 ± 2.3 [20] 3.5 ± 4.7 [  6]    NS
Peritoneal metastasis
Negative 2.5 ± 2.5 [61] NS 6.7 ± 6.6 [31] NS < 0.001
Positive 2.2 ± 2.3 [  4] 3.5 ± 4.7 [  1]    NS
Liver metastasis
Negative 2.5 ± 2.5 [61] NS 6.5 ± 6.6 [32] NS < 0.001
Positive 1.6 ± 1.5 [  4]      —
[  ], number of patients.
NS, not significant.
† Vertical analysis:  statistical difference between specific variables in the same gender.
‡ Horizontal analysis:  statistical difference in each specific variable between males and females.
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There was a positive correlation in both
males and females between preoperative levels
of plasma leptin and the BMI, as shown in
Fig. 1.
Table 4 compares plasma leptin levels be-
fore and after surgery.  Statistically significant
decreases were observed postoperatively.
Discussion
Circulating leptin, which is a product of the
obese gene, provides feedback information on
the size of fat stores to central obese receptors
that control food intake and body weight ho-
meostasis.  Recent studies of plasma leptin
levels in patients with obesity or metabolic dis-
order have given us a wealth of novel informa-
Fig. 1.  Correlations between preoperative levels of plasma leptin and body mass index (BMI).
tion; however, little knowledge was given about
plasma leptin levels of patients with malignant
tumors.  Masuzaki et al. (1997) reported that
plasma leptin levels were markedly elevated in
patients with hydatidiform mole or choriocarci-
noma and were reduced after surgical treatment
or chemotherapy, suggesting nonadipose tissue
production of leptin; namely, placental tropho-
blasts and amnion cells from the uteri of preg-
nant women.  Since breast cancer has been as-
sociated with obesity and reproductive hor-
mones, leptin levels of patients with carcinoma
in situ of the breast were examined and ana-
lyzed for putative involvement of leptin in the
etiology of breast cancer (Mantzoros et al.,
1999).  A possible association has been review-
ed between the cancer-associated anorexia-
cachexia syndrome and leptin (Inui, 1999).
Table 4.  Comparisons of pre- and postoperative plasma leptin levels
   Stage Leptin (ng/mL) P-value
Preoperative Postoperative
I and II
Male [45] 2.8 ± 2.7 1.3 ± 1.0 0.0010
Female [25] 7.0 ± 6.9 3.9 ± 3.9 0.0387
III and IV
Male [20] 1.7 ± 1.7 0.9 ± 0.5 0.0225
Female [  7] 4.6 ± 5.0 1.8 ± 1.3 0.1059
[  ], number of patients.
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However, systematic analyses of leptin levels in
patients with malignant tumors and its clinical
implications have not yet been studied.
In this series, plasma leptin levels, as a
whole, including both males and females, de-
creased along with stage progression in gastric
cancer patients (Table 1).  As reported previ-
ously, there is a gender difference in leptin
levels (Maffei et al., 1995; Havel et al., 1996;
Giannini et al., 1999), and therefore, these levels
were analyzed separately for males and fe-
males.  Leptin levels were consistently higher in
females than males when we compared them in
the same stage.  There was a clear reduction in
leptin with stage progression in both males and
females, as shown in Table 2.
Patients with recurrent tumors from gastric
cancer have a serious nutritional disorder due to
gastrointestinal passage failure of oral food
intake.  In this study, patients with recurrent
cancer showed the lowest leptin levels among
groups of patients including those who under-
went gastrectomy of the primary tumor.  More-
over, significant postoperative decreases in lep-
tin levels were observed.  However, there were
no statistically significant relationships be-
tween leptin levels and specific clinicopatho-
logical findings.  These findings may indicate
that plasma leptin levels do not involve factors
relevant to specific tumor progression but
involve tumor-related nutritional status due to
tumor progression and/or due to limitation of
oral food intake during a relatively short period
after gastrectomy.  Thus, leptin is not only a
simple marker of obesity in humans but also a
marker of tumor progression and/or nutritional
status in patients with malignant tumor.
BMI is an index of obesity and there is no
gender difference in BMI, as shown in Table 2.
Leptin levels correlated positively with BMI
when data were analyzed separately between
males and females (Fig. 1).
We conclude that leptin concentrations in
the circulation have been indicated as a simple
marker of the obesity; however, the role of lep-
tin is exerted in not only metabolic disorders but
also in tumor-bearing status, and it is also a use-
ful nutritional marker for patients with malig-
nancy.  We notice that we have little adequate
markers for evaluating postoperative nutritional
status and/or quality of life when surgeons
analyze the superiority of operative procedures
from various reconstruction methods of the
alimentary tract for patients with gastric cancer.
Postoperative long-term follow-up of the plas-
ma leptin level as a marker may be useful for
these analyses.
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